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Mass spectrometry plays a very visible role in biopharmaceutical industry, although its use in
development, characterization, and quality control of protein drugs is mostly limited to the
analysis of covalent structure (amino acid sequence and post-translational modifications).
Despite the centrality of protein conformation to biological activity, stability, and safety of
biopharmaceutical products, the expanding arsenal of mass spectrometry-based methods that
are currently available to probe higher order structure and conformational dynamics of
biopolymers did not, until recently, enjoy much attention in the industry. This is beginning to
change as a result of recent work demonstrating the utility of these experimental tools for
various aspects of biopharmaceutical product development and manufacturing. In this work,
we use a paradigmatic protein drug interferon -1a as an example to illustrate the utility of
mass spectrometry as a powerful tool not only to assess the integrity of higher order structure
of a protein drug, but also to predict consequences of its degradation at a variety of
levels. (J Am Soc Mass Spectrom 2010, 21, 323–337) © 2010 American Society for Mass
SpectrometryPharmaceutical products based on biopolymersrepresent an important and rapidly growing partof the therapeutic arsenal of modern medicine [1].
While a few of such medicines are based on polysac-
charides [2] and nucleic acids [3], protein drugs [4, 5]
constitute the largest fraction of this segment. Nearly
200 protein-based products have been already ap-
proved worldwide with nearly a thousand more either
in clinical studies, or in various stages of the approval
process [6]. Protein therapeutics fundamentally differ
from the traditional small-molecule medicines in many
ways, perhaps the most obvious being the sheer size of
the active pharmaceutical ingredients. The biopharma-
ceutical products range in size from several kDa (e.g.,
insulin) to nearly 1 MDa (e.g., botulinum toxin), vastly
exceeding the molecular weight typical of small mole-
cule drugs. This quantitative difference gives rise to an
important qualitative distinction between the “tradi-
tional” small molecule medicines (where the covalent
structure alone is the sole determinant of the three-
dimensional structure and, ultimately, the therapeutic
properties of the drug) and the protein pharmaceuticals
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noncovalent contacts not only inevitable, but in fact the
defining element of their three-dimensional structure).
The unique three-dimensional organization of pro-
teins, or higher order structure, is vital not only for their
function, but also for many other aspects of their
behavior. Proteins that are not folded properly are
usually prone to aggregation both in vitro and in vivo,
and are frequently a target for various degradation
pathways both inside and outside the cell. Since a
unique conformation is critically important for the ability
of a protein drug to interact with its physiologic targets, a
failure to fold or maintain the native conformation at any
time before or during administration would obviously
have a negative impact on efficacy. Even partial unfolding
that does not affect the structural elements of a protein
drug critical for its function may have grave conse-
quences, as such structurally compromised species are
typically prone to aggregation [7]. In addition to the
negative impact on efficacy due to the protein drug loss,
aggregation may trigger immune response, thereby ad-
versely affecting the safety profile of the protein drug [8].
The central role played by higher order structure and
conformational integrity in determining potency, stabil-
ity and safety of protein therapeutics makes character-
ization of protein conformation a critical element for
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mulating of biopharmaceutical products. Furthermore,
since the covalent structure alone does not define a
protein drug, the ability to provide accurate and de-
tailed characterization of protein conformation and
dynamics will also be very important in establishing
comparability (“sameness”) of protein drugs and the
original approved drug products following a manufac-
turing process change. Recognition of the prominent role
played by protein conformation and dynamics in estab-
lishing bioequivalence makes characterization of higher
order structure of biopharmaceutical products especially
important in light of the emergence of follow-on biologics
[9] and the need to effectively regulate them [10, 11].
In the past several decades biophysics have amassed
an impressive armamentarium of experimental tech-
niques to probe various aspects of protein conformation
and dynamics [12]. In particular, X-ray crystallography
and high-resolution NMR are able to provide, in many
cases, detailed structure of proteins and their com-
plexes, contributing knowledge that has been truly
invaluable for the development of many bio- and small
molecule pharmaceutical products [13]. Unfortunately,
these two powerful techniques have inherent limita-
tions that often make their application to the analyses of
biopharmaceutical products impractical. For example,
X-ray crystallography, by definition, requires that the
protein be crystallized before analysis. This makes it
impossible to carry out direct examination of the pro-
tein drug conformation under relevant production/
storage conditions (e.g., protein drug substance, prod-
uct or dosing solution) or physiologic conditions (e.g.,
mimicking the environment encountered by the protein
post-administration). Furthermore, partially unfolded
states are less likely to crystallize, thereby generating a
bias against non-native conformations that may be
present in solution. A sister technique that is capable of
probing non-native ensembles of proteins directly in
solution, small-angle X-ray scattering [14], does not
provide detailed structural information.
Unlike X-ray crystallography, high-resolution NMR
is capable of revealing intimate details of both higher
order structure and conformational dynamics of pro-
teins. However, it still is restricted in terms of the
physical size of the protein systems it can handle
routinely, placing the majority of biopharmaceutical
products out of its reach. Therefore, it is not surprising
that routine analyses of conformation and stability of
protein drugs still rely on classical biophysical methods,
such as various spectroscopic techniques (especially
circular dichroism, fluorescence, UV-absorption, and
FTIR spectroscopy), light scattering, calorimetry, as
well as analytical centrifugation and size exclusion
chromatography [15–17]. Most of these techniques have
an advantage of being able to probe the conformational
properties of macromolecular drugs in more relevant
environments (i.e., those matching or closely mimicking
formulations). However, they are typically focused on
one particular aspect of higher order structure and failto provide a detailed and comprehensive characteriza-
tion of conformation and dynamics.
Mass spectrometry is another powerful analytical
technique that is capable of characterizing biopolymer
structure at a variety of levels, although most current
applications of MS in the biopharmaceutical industry
are focused on characterizing the covalent structure of
proteins (amino acid sequence and post-translational
modifications, PTMs). It is the ability to map both
enzymatic and nonenzymatic PTMs with high sensitiv-
ity and unprecedented accuracy that made MS a staple
in characterization of biopharmaceutical products [18,
19]. However, in many cases, there is no straightfor-
ward correlation between the presence or absence of
certain PTMs within the protein molecule and its con-
formational stability or functional properties. Indeed,
the consequences of PTMs in terms of stability and
functional competence of biopharmaceutical products
are highly context-dependent and vary significantly
from one system to another. While many PTMs are
detrimental for the protein conformational stability
(e.g., disulfide scrambling), some others appear to be
fairly inconsequential, and can be easily tolerated by a
protein without any noticeable impact on its function,
stability, or safety profile. At the same time, loss of
native conformation may be triggered by a variety of
factors, many of which have nothing to do with either
enzymatic or nonenzymatic PTMs, and protein unfold-
ing is not necessarily accompanied by alterations of its
covalent structure.
Therefore, focusing protein drug characterization
efforts on detecting PTMs may generate both false-
positive and false-negative outcomes as far as confor-
mation and stability are concerned. Furthermore, the
complexity exhibited by many protein therapeutics in
terms of both sheer size and structural heterogeneity
makes precise mapping of all covalent alterations in
many cases a very difficult, if not an unfeasible, task.
Clearly, there is a need in the biopharmaceutical indus-
try to have new tools capable of detecting and charac-
terizing changes in protein conformation that do not
have to rely on techniques targeting covalent structure.
Development of MS-based experimental strategies to
probe higher order structure and dynamics of biopoly-
mers, proteins in particular, have been a focal point of
extensive research efforts, following the early recogni-
tion of the great potential of MS in this vast field nearly
two decades ago [20–24]. An impressive arsenal of MS
techniques to probe noncovalent structure was devel-
oped as a result of these efforts [25], many of which
proved highly successful in dealing with a variety of
problems in biophysics and structural biology.
However, outside of academic laboratories, the em-
brace of these methodologies by industrial researchers
has been somewhat limited until recently due to a
variety of reasons. Some techniques, such as covalent
cross-linking [26], have inherently low yields and,
therefore, are not well suited for the specific needs of
biopharmaceutical industry, where partial loss of struc-
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small fraction of proteins on the background of natively
folded species. Methods that rely on direct ESI MS
analysis of higher order structure, such as probing
noncovalent assemblies [27–29] or analysis of protein
ion charge state distributions [30], are frequently met
with some skepticism due to the very nature of these
measurements. Indeed, direct ESI MS measurements
require that the proteins be placed into the so-called
“electrospray-friendly” solvents (aqueous solutions of
volatile salts), making structural characterization in a
relevant environment (e.g., formulation buffer) nearly
impossible. These limitations notwithstanding, probing
noncovalent associations by direct ESI MS is increas-
ingly used in the drug discovery process [31], including
optimization of protein drugs [32]. Charge state distri-
bution analysis of protein ions in ESI MS is also beginning
to enjoy recognition as a useful tool for comparability
studies of related biopharmaceutical products [33].
Among MS-based techniques targeting protein higher
order structure and dynamics, hydrogen/deuterium
exchange (HDX) with MS detection [34–38] has dem-
onstrated the greatest promise vis-à-vis conformational
analysis of biopharmaceutical products. The technique
is reliable, robust and sensitive, and is capable not only
of detecting the presence of (partially) unfolded species
in solution, but also localizing the protein segments
with anomalous protection levels. This latter feature is
particularly appealing as a means of mapping interac-
tion sites, and is now actively evaluated for the purpose
of optimizing the process of screening small molecule
drug candidates [39–41]. Furthermore, the ability of
HDX MS to detect and characterize structurally com-
promised proteins on the background of the natively
folded species in highly complex matrices makes it a
very promising tool for conformational characterization
of protein drugs [42, 43] and may open up new and
exciting opportunities in drug formulation.
However, a complete embrace of this technique by
the industry practitioners, as well as its better utiliza-
tion, require that several questions be answered to
better define its capabilities and limitations, particularly
within the context of specific requirements of biophar-
maceutical industry and regulatory agencies. For exam-
ple, can MS-based methods provide information that
cannot be obtained by classical methods commonly
employed in the industry? How relevant is the infor-
mation derived from MS characterization of protein
drugs in terms of their conformational integrity, stabil-
ity and functional competence? Can MS be used in
comparability studies?
In this work, we use an example of a glycoprotein
interferon-1a, the active pharmaceutical ingredient in
several commercial biopharmaceutical products, in an
attempt to address these questions. The work presented
here clearly demonstrates that the value of MS extends
far beyond mere detection of misfolded species. MS-
based methods to probe higher order structure generate
information that has high predictive value for analysisof properties and behavior of protein therapeutics. As
such, these methodologies present an extremely valuable
complement to the battery of “classic” biophysical tech-
niques already employed in biopharmaceutical industry.
Detection of Conformational Changes in
a Biopharmaceutical Product: Alkylation
of Interferon as a Model of Protein
Drug Degradation
Interferon-1a (IFN) is a member of the type I interferon
family, a group of homologous cytokines that display
broad biological activity, including activation of anti-
viral response, immunoregulation, and anti-tumor
activity [44, 45]. IFN is the most widely prescribed
disease-modifying therapy for multiple sclerosis [46], a
chronic, progressive autoimmune disorder of the cen-
tral nervous system [47]. As is the case with many
proteins, IFN has a problematic propensity to misfold,
which leads to activity loss, aggregation, and increased
immunogenic response [8]. This structure loss can be
accelerated by a variety of factors, such as chemical
modifications, surface binding, exposure to elevated
temperatures, lyophilization, etc. Some nonenzymatic
PTMs have been long suspected to act as likely triggers
of misfolding, although establishing a firm correlation
between such covalent modification events and the
integrity of the protein higher order structure has
proved difficult.
Recently, we demonstrated that both charge state
distribution analysis of IFN ions in ESI MS and HDX
MS readily provide evidence of IFN partial unfolding
resulting from a single specific nonenzymatic PTM,
alkylation of the sole free cysteine residue in IFN
(Cys-17, see Figure 1) with N-ethylmaleimide [42]. This
nonenzymatic PTM dramatically reduces the activity of
the protein (a 50%–90% decrease of IFN antiviral activ-
ity), which is likely to be mediated by changes in the
protein conformation. However, classic biophysical
techniques yielded mixed results when applied to de-
tect this putative change: only size-exclusion chroma-
tography (SEC) was able to make a clear distinction
between the intact and NEM-alkylated forms of IFN,
while spectroscopic techniques either failed to detect
the conformational changes or reported differences that
were not adequate for making a clear distinction [42].
On the contrary, application of MS-based methods
for probing higher order structure provided clear and
unequivocal evidence that the native conformation of
IFN was compromised as a result of NEM-alkylation.
For example, direct ESI MS analysis of IFN and NEM-
IFN following buffer exchange to an electrospray-
friendly solvent reveals qualitative differences between
the two forms of the protein. Ions of intact IFN exhibit
a narrow charge state distribution with low charge
density, as is expected for compact, tightly folded
macromolecular species, while the charge state distri-
bution of the NEM-IFN ions is clearly bimodal (Figure
326 KALTASHOV ET AL. J Am Soc Mass Spectrom 2010, 21, 323–3372). Presence of the higher charge-density ions in ESI
mass spectrum of NEM-IFN clearly signals that a frac-
tion of the protein molecules fail to maintain the com-
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Figure 1. Higher order structure (top) and amino acid sequence
(bottom) of IFN with elements of secondary structure labeled
according to a commonly accepted nomenclature [44]. Colored
residues are common targets of nonenzymatic or designer PTMs:
orange, Cys-17 (alkylation, oxidation, formation of external disul-
fides, internal disulfide scrambling, replacement with Ser in
interferon 1b, PEGylation via thiol-reactive group); yellow,
Cys-31 and Cys-141 (disulfide scrambling); cyan, Lys-19 (glycation
[86]); magenta, methionine residues (oxidation); and green,
Asn-90 (variable glycosylation and deglycosylation).
1000 1500 20
0
25
50
75
100
re
la
tiv
e 
ab
un
da
nc
e
+
+12
+13
+14
+15
+16
Figure 2. ESI mass spectra of intact (blue) a
aqueous 100 mM ammonium acetate before MS a
due to the presence of several glycoforms. Gra
acquired under strongly denaturing conditions (50%pact native structure. With some caution, it may even be
possible to estimate the fractional concentrations of the
(partially) unfolded and compact (tightly folded) pro-
tein species in solution based on the abundance of high-
and low-charge density protein ions in ESI MS [48].
Although the presence of the NEM-alkylated residue
within IFN can be easily deduced from the mass shift of
NEM-IFN ions (see inset in Figure 2), the detection of
partial unfolding here is based entirely on charge,
rather than mass, measurements and, therefore, does
not depend on the ability to detect any changes in
covalent structure concurrently with (or before) the
conformational analysis. In fact, this technique can
detect changes in protein compactness triggered by
nonenzymatic PTMs that do not alter the protein mass
(e.g., disulfide scrambling).
It must be said that the extent of multiple charging of
the NEM-IFN species representing the less compact
conformations (charge states 11 through 14 in Fig-
ure 2) still implies the presence of some residual struc-
ture. Indeed, the average charge density of IFN ions in
ESI mass spectrum acquired under denaturing condi-
tions (gray trace in Figure 2) is noticeably higher. This
suggests that the solvent accessible surface area of
“non-compact” conformers of NEM-IFN, whose pres-
ence under near-native conditions is revealed by the
protein ion charge state distribution analysis, is lower
compared to the fully denatured species of IFN [49, 50].
However, this technique yields only a global measure of
conformational “disorder” and, therefore, cannot pro-
vide any information that would allow these unfolding
events to be localized within the protein structure.
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327J Am Soc Mass Spectrom 2010, 21, 323–337 NEW ROLE FOR MS IN ANALYSIS OF PROTEIN DRUGSThis gap can be easily filled by HDX MS, which
provides local information on backbone dynamics
when the exchange reaction in solution is supple-
mented by proteolysis under the slow exchange condi-
tions and MS analysis. HDX MS easily identifies several
segments in NEM-IFN whose stability is greatly com-
promised by alkylation of Cys-17 [42]. One example is
shown in Figure 3, where the evolution of the isotopic
distribution of a peptic fragment [L88-L102] is traced
over first 120 s of H/D exchange. Very slow uptake of
deuterium is exhibited by the fragment derived from
intact IFN (blue trace), while the protein alkylation
results in a dramatic acceleration of the exchange kinet-
ics of this segment. Presence of several such segments
whose exchange kinetics is significantly altered by the
alkylation event clearly signals a change in conforma-
tion and/or dynamics induced by the alkylation, con-
sistent with the conclusions of the protein ion charge
state distribution analysis (vide supra). Importantly,
these measurements do not require that the protein be
transferred to an electrospray-friendly buffer before the
isotopic labeling, thereby allowing the conformational
analysis to be carried out under relevant conditions
(e.g., in the formulation buffer), since isolation of the
protein drug material from the commercial product is
often viewed as a step capable of altering its structural
integrity [51]. Furthermore, the ability to localize the
unfolding events within the protein sequence provides
valuable information that can be used to predict the
functional consequences of such partial unfolding. Just
like the charge state distribution analysis, characteriza-
tion of conformation and dynamics by HDX MS does
not require any prior knowledge of the nonenzymatic
PTMs that may be present in the protein drug. In fact,
identification of all peptic fragments carried out before
HDX MS analysis, is likely to detect most PTMs within
the protein. Even if some of them escape the detection,
this would obviously make no impact on the validity of
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Figure 3. Evolution of isotopic distributions
(blue) and NEM-alkylated (red) IFN throughou
reaction is indicated with a gray trace (isot
Location of this peptide within the amino acid
with permission from [42].the HDX MS analysis of protein conformation and
dynamics.
What Do the Results of the HDX MS
Conformational Analysis Tell Us About
the Likely Changes in the Properties of
the “Degraded” Protein Drug?
The detailed information on the backbone protection of
IFN and NEM-IFN provided by HDX MS measurements
allows the conformational properties of intact and alky-
lated forms of the protein to be compared directly. Per-
haps the most important conclusion derived from the
HDX MS work is the dramatic destabilization of helix D
by the PTM event which affects a remote site in the amino
acid sequence of this protein [42]. Although this segment
is very distant from the residue affected by alkylation
(Cys-17) within the protein sequence, it is proximal to the
Cys-17 side chain within the three-dimensional structure
of the protein (Figure 4a).
Analysis of the crystal structure of IFN (PDB id
1AU1 [52] makes it clear that modification of Cys-17
with NEM introduces a significant steric clash in the
protein interior, which distorts helix packing, thereby
adversely affecting the stability of the protein higher
order structure. One extreme scenario of “relieving”
this steric clash is presented in Figure 4b, where a total
loss of secondary structure within helix D converts it to
a flexible loop, thereby allowing the bulky NEM group
to be accommodated within the protein structure. An-
other plausible scenario involves conversion of helix A
to a flexible loop (this element of the secondary struc-
ture appears to be highly dynamic even in the absence
of alkylation [42] and may also explain the possibility of
forming a disulfide-linked IFN dimer despite seques-
tration of Cys-17 side chain in the protein interior [53]).
Since the alkylation increases the dynamic character of
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328 KALTASHOV ET AL. J Am Soc Mass Spectrom 2010, 21, 323–337both helices (A and D), NEM-IFN is likely to transiently
sample conformations where either or both of these
elements of secondary structure are compromised ei-
ther through more frequent local structural fluctuations
or via cooperative unfolding of the entire elements. We
chose to present in Figure 4 the scenario where helix D
melts, while helix A remains intact, due to its relevance
for the mechanism of IFN deactivation (vide infra).
Even transient unfolding of either helix A or D (or
both) would inevitably increase the aggregation pro-
pensity of IFN by exposing the hydrophobic residues,
which are sequestered in the interhelical interfaces in
the native structure of IFN (Figure 4c and d). In fact, we
have noticed diminished stability of NEM-IFN in solu-
tion compared to intact IFN in the course of our
experimental work. These conformational changes at
the IFN monomer level and the presence of aggregates
in NEM-IFN solution are also likely to increase the
likelihood of an immune response [8, 17].
Conformational Changes Detected by
HDX MS: Relevance for the Functional
Competence of the Protein Drug.
Verification by “Native” ESI MS
The analysis of the backbone flexibility maps of IFN and
NEM-IFN also provides important clues regarding the
(a)
(c)
Figure 4. Location of the 88–102 segment (hig
[1AU1, (a)] with respect to Cys-17 (highlighted
steric clashes within the native structure, which c
the 88–102 segment (b). Side chains of hydroph
protein interior [highlighted in green, (c)], but
structural element (d).molecular mechanism of inactivation of the modifiedform of IFN. IFN exerts its action by binding to the
ectodomains of two transmembrane interferon recep-
tors, IFNAR1 and IFNAR2 (Figure 5a). The assembly of
this ternary complex in the extracellular space is re-
quired for bringing the cytoplasmic domains of IFNAR1
and IFNAR2 into close proximity. This latter step leads
to activation of the JAK-STAT signaling pathway,
which triggers a convoluted sequence of events that
regulate the activity of interferon-stimulated response
element (ISRE) in the nucleus [45, 54]. IFNAR1 and
IFNAR2 cannot interact directly with each other with-
out IFN mediation, and the assembly of the ternary
complex is believed to proceed via IFN binding to the
high-affinity receptor IFNAR2, followed by recruitment
of the low affinity receptor IFNAR1 [45], Figure 5b. The
latter event is accompanied by a conformational change
in the ectodomain of IFNAR1, which propagates to its
cytoplasmic domain, thereby initializing signal trans-
duction within the cell [55].
The IFNAR 1 and IFNAR2 binding interfaces re-
vealed by mutagenesis [44, 56] are localized in two
distinct parts of the IFN molecule (Figure 6c). Interest-
ingly, comparison of this interface map with the IFN
flexibility diagram deduced from the HDX MS mea-
surements (Figure 6a) suggests that the protein seg-
ments forming the interface with the high-affinity re-
ceptor IFNAR2 are among the most dynamic (least
ted in red) within the crystal structure of IFN
ange). Alkylation of Cys-17 inevitably leads to
removed by unfolding of the helix D containing
residues within helix D are sequestered in the
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tide chain flexibility has been suggested to play an
important role in protein interactions [57], and transient
structural disorder was shown in the past to be an
important facilitator of protein binding to small ligands
[58] and other proteins [59].
Importantly, increased fluctuation within the receptor-
binding interface region of human growth hormone
(hGH) was recently linked directly to the increased
free-energy of the protein-receptor binding [60], which
belongs to the same hematopoietic super-family that
includes type I interferons [61]. The two proteins (hGH
and IFN) are highly homologous, so much so that hGH
was used in earlier homology modeling of IFN and
INF/IFNARs binding [61, 62]. Helix 1 of hGH is notice-
ably more stable compared with its cousin helix A of
IFN; however, introducing a structure-destabilizing
mutation in helix 1 leads to a noticeable increase in the
receptor binding affinity [60]. Therefore, it should not
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If the dynamic character of helix A does in fact
catalyze formation of the IFN/IFNAR2 complex, a
modest flexibility increase within this element of IFN
induced by alkylation of Cys-17 would be unlikely to
disrupt the binding. Therefore, the first step in IFN/
IFNARs ternary complex assembly at the cell surface is
unlikely to be important for the activity loss of NEM-
IFN. However, binding of IFN or NEM-IFN to IFNAR2
is almost certain to cement the structure of the IFN
segments located in the interface region, similar to the
stabilization of helix 1 observed upon hGH binding to
its receptor [60]. In this case, partial or complete melting
of helix D would remain the only possible way to avoid
the steric clash introduced by NEM-alkylation of Cys-17
(Figure 4b).
The next step in the ternary complex assembly involves
association of the low-affinity receptor IFNAR1 with
IFNAR1
AT pathway activation by IFN initiated by its
adapted from [45]; and the proposed sequence
plex IFNAR2/IFN/IFNAR1 (b).
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face of IFN maps on to the most stable region of the
protein surface (Figure 6a and c), which is hardly
surprising. Indeed, according to the accepted scenario,
at this stage of the ternary complex assembly IFN serves
as a binding template to which a flexible partner
(IFNAR1) adapts [63]. This consideration is particularly
important within the context of the observation (de-
duced from the HDX MS measurements [42]) that the
alkylation of Cys-17 results in significant destabilization
of the IFNAR1-binding interface region of IFN (Figure
6b). The increase of IFN flexibility, which maps almost
perfectly to the binding interface (compare b and c in
Figure 6), is very likely to be highly detrimental to the
IFN/IFNAR1 interaction.
The effect of alkylation is likely to be even more
pronounced within the context of the ternary complex
assembly, where the IFN/IFNAR1 binding occurs via
recruitment of IFNAR1 to the IFN · IFNAR2 binary
complex. As already mentioned, the expected stabiliza-
tion of helix A in NEM-IFM following its association
with IFNAR2 would result in additional stress on helix
D due to the presence of a bulky NEM group sand-
wiched between them (Figure 4b). As a result, helix D is
even less likely to be able to maintain a native-like
structure within the NEM-IFN · IFNAR2 complex com-
pared to NEM-IFN alone. Therefore, one should expect
the stability of the ternary complex IFNAR1 · NEM-
IFN · IFNAR2 to be greatly diminished compared with
IFNAR1 · IFN · IFNAR2.
Analysis of the HDX MS data presented in this
section suggests that the NEM-alkylation of IFN should
impact its ability to bind the low affinity receptor and
assemble a ternary complex to a much more significant
extent compared to the effect (if any) on the IFN
interaction with the high affinity receptor. A relatively
easy and convenient way to assess the predictive value
of these conclusions is provided by “native mass spec-
trometry,” a technique that relies on the unique ability
of ESI to preserve noncovalent complexes upon their
transition from solution to the gas-phase [28]. Here we
apply this technique to monitor IFN interactions with
its receptors and the effect exerted by NEM-alkylation
on these processes.
ESI MS of IFN/IFNAR2 mixture acquired under
near-native conditions (aqueous solution of 100 mM
ammonium acetate) using a hybrid quadrupole/time-
of-flight mass spectrometer (QStar-XL; ABI/SCIEX, To-
ronto, Canada) provides clear evidence of a binary
complex formation. The binding appears to be complete
when the proteins are present in solution in the M
concentration range (e.g., no signal of free IFNAR2 is
present in the mass spectrum alongside IFN or
IFN · IFNAR2, as long as there is excess of IFN in the
mixture, see Figure 7). This is consistent with the earlier
results provided by SEC [64] and a low-nM binding
constant estimated for this interaction [65]. Importantly,
the appearance of ESI mass spectra does not change
when IFN is substituted with NEM-IFN, apart fromsmall mass shifts due to alkylation (data not shown),
consistent with the predictions generated in the course
of the analysis of HDX MS data (vide supra).
Analysis of the IFNAR1/IFN interaction might be
somewhat trickier, since the binding energy is signifi-
cantly weaker compared to the high affinity receptor
(KD is estimated to be in the high sub-M range [65]. As
a result, earlier attempts to detect the IFNAR1 · IFN
using SEC failed [66]. ESI MS appears to be a much
more sensitive technique in this regard, demonstrating
not only the formation of a 1:1 complex in solution, but
also the absence of unbound IFNAR1 species (when
excess IFN is present), as long as the protein concentra-
tions in the mixture are maintained at least in the low
M range (Figure 8a). However, the ESI mass spectrum
of the NEM-IFN/IFNAR1 mixture acquired under
identical conditions clearly shows that the binding is
affected by the alkylation (Figure 8b). Even though ionic
signal of IFNAR1 · IFN complex is present in the mass
spectrum, contributions of both unbound NEM-IFN
and free IFNAR1 are also prominent. Since both pro-
teins are present in the mixture at low M concentra-
tions, the dissociation constant of the binary complex
must be in the M range or higher, an order of
magnitude above that of the IFNAR1 · IFN complex.
A very similar effect is exerted by IFN alkylation
upon the stability of the ternary complex IFNAR1 ·
IFN · IFNAR2. ESI MS provides strong evidence of
complete binding in the IFNAR1/IFN/IFNAR2 mix-
ture (Figure 9). Even though the ionic signals of some of
the constituents of the ternary complex are observed
alongside the ternary complex (e.g., IFNAR2 and
IFN · IFNAR2 in the mass spectrum shown in Figure 9),
the complementary components (e.g., IFNAR1 · IFN
Figure 7. ESI MS of IFN/IFNAR2 interaction in the presence of
excess IFN. Note that free IFNAR2 is absent from the spectrum (a
reference mass spectrum of free IFNAR2 is shown in gray).and IFNAR1) are clearly absent. The situation changes
ide t
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with the alkylated form (top trace in Figure 9). Even
though this spectrum provides unequivocal evidence
that the ternary complex is formed in solution, the
presence of the binary complex NEM-IFN · IFNAR2
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Figure 8. (a) ESI MS of IFN/IFNAR1 interaction
is absent from the spectrum (a reference mass sp
of NEM-IFN/IFNAR1 interaction in the presenc
and IFNAR1 are present in the spectrum alongs
Figure 9. ESI MS of NEM-IFN interaction with IFNAR1 and
IFNAR2 in the presence of excess NEM-IFN and IFNAR2 (red
trace). Note that both free IFNAR1 and a binary complex NEM-
IFN · IFNAR2 are present in the spectrum alongside the ternary
complex. Mixing intact IFN with the two receptors results in
complete elimination of either free IFNAR1 or the binary complex
IFN · IFNAR2 depending on the relative abundance of each of the
three proteins (blue trace).alongside free IFNAR1 clearly suggests that the binding
does not go to completion despite the fact that all
participating proteins are present in solution at low M
concentrations.
It is quite remarkable that native ESI MS confirms the
conclusions drawn from the HDX MS experiments
regarding the consequences of the PTM-triggered con-
formational changes for the ability of the protein to
interact with its cognate receptors. Taken together,
these two powerful techniques provide a means to
determine the molecular basis of the protein drug
inactivation following deleterious PTMs or other stress-
induced degradation events.
Conformational Analysis of the Model
Protein: Predictive Value for Identifying
the “Weak Links” in the Protein Chain
Although alkylation of Cys-17 with NEM considered in
the preceding sections was chosen only as a model of
IFN degradation, analysis of the ensuing conforma-
tional changes provides important lessons regarding
the likely consequences of many nonenzymatic PTMs
that may affect IFN either by chance or by choice.
Indeed, several covalent modification events that are
known to occur under certain conditions target either
Cys-17 or its immediate neighbors. For example, pro-
tein drug exposure to reactive oxygen species during
manufacturing or storage frequently results in oxida-
tion [67], one of the most common covalent modifica-
tions in biopharmaceutical products [68]. The results of
unreported work carried out in our laboratories suggest
that controlled forced oxidation of IFN with H2O2
(which oxidizes three out of four methionine residues to
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332 KALTASHOV ET AL. J Am Soc Mass Spectrom 2010, 21, 323–337tially to sulfenic acid, SOH, a common but frequently
unstable form of an oxidized thiol group [69] does not
result in a significant change of its biological activity
measured by a standard anti-viral assay. However,
more extensive oxidation converts Cys-17 to sulfinic
acid (SO2H), which appears to affect negatively the
ability of IFN to bind the low-affinity receptor, IFNAR1,
as revealed by native ESI MS measurements (data not
shown). Once again, the physical size of the adduct
formed on the Cys-17 side chain appears to be a factor
destabilizing the critical element of the IFN/IFNAR1
interface, as was the case with NEM-alkylation.
Another deleterious nonenzymatic PTM that targets
Cys-17 is disulfide scrambling, a phenomenon that can
also be detected and characterized using various mass
spectrometry-based strategies [70]. Although extensive
efforts to observe scrambling under native conditions
have been unsuccessful, IFN denaturation in the pres-
ence of reducing agents does lead to formation of IFN
isomers with non-native disulfide bonds (i.e., Cys-17 is
oxidized, while either Cys-31 or Cys-141 is reduced).
We and others also demonstrated that under certain
conditions Cys-17 may become involved in formation of
an external disulfide bond, leading to formation of a
covalent IFN dimer [53]. An attempt to address this
potential vulnerability of Cys-17 was made in the
design of the earliest commercial IFN product, Betase-
ron, by substituting this residue with a relatively inert
serine [71]. However, this form of IFN (interferon 1b)
also lacks a carbohydrate chain. Glycosylation is often a
critical element defining the stability of protein phar-
maceuticals, and de-glycosylation is particularly dam-
aging for IFN, where the carbohydrate chain shields a
relatively hydrophobic patch on the protein surface
from the solvent [72]. As a result, the biological activity
of the carbohydrate-free form of IFN is significantly
lower than that of the wild type protein, while its
aggregation propensity is much higher [72].
Interestingly, Cys-17 was also proposed in the past
as a target for PEGylation, a “designer” PTM that is
frequently used to enhance solubility and improve phar-
macokinetic profile of protein drugs [73]. PEGylation
was shown to be beneficial to IFN, where it improved
the pharmacokinetic profile of this protein by reducing
its tendency to aggregate while maintaining its activity
[74, 75]. However, one commonly cited problem with
the PEGylation of biopharmaceutical products is the
difficulty in controlling the specificity of conjugation,
which frequently generates an ensemble of protein
molecules where the polymer chains are attached to
different sites [76]. Since there is only one free cysteine
residue in the protein, a suggestion was made to
increase the homogeneity of IFN PEGylation by using a
thiol-reactive PEG chain [77, 78]. While the initial report
on this PEG-IFN conjugate was encouraging [77], no
follow-up preclinical work was reported in the following
decade, in contrast to other products of IFN PEGylation
showing excellent results in preclinical investigation
and entering clinical trials. This lack of action in such adynamic field suggests that the use of a thiol-reactive
PEG chain to specifically target Cys-17 met with insur-
mountable difficulties, most likely due to the instability of
the conjugate, a dramatic reversal of the trend that is
observed when solvent-exposed amino groups serve as
PEGylation sites [74, 75]. This example further highlights
the value of HDX MS work that identifies Cys-17 as a
rather troublesome site of IFN molecule.
HDX MS as a Protein Drug
Comparability Tool: Establishing
Equivalence at the Higher Order
Structure Level
In the specific model of IFN degradation considered in
the preceding sections, the backbone protection of the
88–102 segment serves as a convenient reporter of the
protein conformational integrity. Because of the prox-
imity of this segment in the 3D structure of IFN to
Cys-17, one of the vulnerable elements of the protein, its
utility as a reporter of protein degradation is likely to
extend well beyond conformational changes triggered
by NEM-alkylation. However, generally speaking it is
not clear a priori which region(s) of the protein will
have their stability diminished as a result of stress or
degradation. Therefore, unbiased analysis of protein
conformation and dynamics should focus not on a
single element of the protein higher order structure, but
rather catalog all conformational changes. Such analysis
should cover the entire sequence of the protein (or at
least as much as possible) and follow the exchange
kinetics over extended periods of time. Capturing the
exchange patterns on different time scales has a poten-
tial to be much more informative compared to simply
taking a single snapshot at an arbitrary selected time
point (e.g., changes in protection patterns on shorter
time scales may reveal compromised functional prop-
erties, while changes at longer time scale may betray the
enhanced aggregation propensity of the protein).
Adaptation of this approach in the biopharmaceuti-
cal sector is likely to make a major impact on facilitating
comparability studies of protein drugs, whose goal is to
establish “sameness” of two (or more) related biophar-
maceutical products. In the case of biopharmaceuticals,
approval to a final product is given in the form of
accepting the specific process of its manufacturing and
formulation. However, the once unquestionable mantra
“the process is the product” has been replaced by
realization that in many cases post-approval changes to
the process (e.g., change of a manufacturing site, pro-
tein production/purification protocol, and/or product
formulation) can be dealt with by establishing the
equivalence of the “new” product to the original one
using “comparability” criteria [51], giving rise to the
concept of “well characterized biological products” [79].
The minimum set of comparability criteria includes
molecular characterization, biological activity relevant
for the therapeutic effect and relative bioavailability or
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play a role in regulation of the so-called biosimilars or
follow-on biologics, “generic” versions of the innovator
protein drugs facing patent expiration, more exhaustive
studies are likely to be needed in this case [51].
In all of these situations, the producer of the drug is
required to prove to the regulatory agencies “same-
ness” of the drug to the original (approved) product.
Effectively, the manufacturer needs to prove drug
equivalence (although the use of the term “identical”
would be preferred, it is realized that in many cases this
is unrealistic for biopharmaceuticals). The absence of
alterations must be demonstrated at several levels,
including covalent structure, purity, conformation
(higher order structure), biological activity, and clinical
behavior in terms of toxicology and efficacy (including
dosage) and immunogenicity. Of particular concern are
possible changes in the higher order structure, includ-
ing those triggered by environmental physical factors,
whose detection is still viewed as lying out of the reach
of current analytical methodology (as applied to biop-
harmaceuticals) [51]. It is precisely in the area of con-
formational analysis that the MS-based experimental
tools, especially HDX MS, can and should play an
important role.
For example, MS-based comparability studies fo-
cusing on conformation and dynamics of two ver-
sions of the same protein drug may assess their three-
dimensional structures and conformational dynamics
by obtaining backbone protection maps using HDXMS.
The goal of such an investigation would be to determine
if there are any protein segments where a statistically
significant difference in protection levels exists between
the two forms (i.e., lies outside of the range of variabil-
ity that is normally observed in conducting these exper-
iments). Detection of such statistically significant differ-
ences in backbone protection patterns would immediately
signal that the two forms of the protein drug are not
equivalent at the molecular level and, therefore, do not
satisfy one of the comparability criteria.
As mentioned above, the HDX MS data would have
to be acquired at various time scales to enable detection
of a variety of relevant dynamic events. This approach
is illustrated in Figure 10a, where the two forms of IFN
were produced using different growth media, a stan-
dard biological source medium (preparation 2) and a
modified synthetic medium (preparation 3), which re-
duces the potential threat of contaminating the growth
media with biologically active agents and provides
more reproducible growth conditions for achieving
higher product consistently. In this study, four indepen-
dent HDX MS experiments were carried out to deter-
mine if there are any statistically significant differences
in protection patterns between these two products. The
results of this comparability study (Figure 10a) indicate
that there are no protein segments exhibiting a statisti-
cally significant difference in backbone protection. This
is in sharp contrast to the results of a similar compara-
bility analysis carried out for the NEM-alkylated formof IFN (using intact IFN as a reference). In the latter
case, several regions can be clearly identified where the
differences between the two forms of the protein exceed
the statistical variability (Figure 10b).
Current Challenges and Future Outlook
Biopharmaceutical products cover a very wide molec-
ular weight range, and IFN is located in the lower half
of this spectrum. While there are a large number of
protein drugs that have either similar or smaller size,
which would also benefit from the conformational
analysis discussed in this article, development of reli-
able tools to probe conformation, and dynamics of
larger proteins is a more urgent task. Larger protein
drugs (such as monoclonal antibodies) are much more
complex, and as the size/complexity of any system
increases, so does the probability that something may
go wrong. This is certainly true in any branch of
technology, and biotechnology is no exception to this
rule. Of particular concern is the possibility of local
unfolding events in large proteins, which can trigger
aggregation, a highly undesirable process as far as
protein therapeutics are concerned. An increase in size
of a protein drug also inevitably translates into elevated
frequency of nonenzymatic PTMs, which often makes
precise mapping of these changes a gargantuan task.
Therefore, availability of a robust, easy-to-use and rea-
sonably high-throughput method to probe conforma-
tional integrity of such large systems directly would
obviously be a boon to the biopharmaceutical industry.
Implementation of HDXMS for conformational anal-
ysis of large (60 kDa) protein drugs faces several
challenges. First, nonspecificity of pepsin cleavage com-
bined with the large physical size of the protein typi-
cally results in a large number of fragment peptides,
which must be identified to extract meaningful HDX
information. This problem is magnified by the frequent
occurrence of glycosylation and disulfide bonds in
protein drugs, which both multiply the sheer number of
candidate peptides that fit a given mass and also make
it more difficult to obtain meaningful sequence infor-
mation using classic MS/MS approaches, such as
collision-activated dissociation (CAD). In many cases,
reliable peptide identification may be achieved only by
using ultra-high-resolutionmassmeasurements (e.g., with
FT ICR MS), applying electron-based ion fragmentation
techniques (ECD or ETD), or using collision-energy de-
pendent data collection in MS/MS experiments (MSE).
Furthermore, even complete identification of all ob-
served peptic fragments does not necessarily result in
complete sequence coverage of a large protein. Indeed,
the necessity to minimize the sample handling time
before MS analysis as a means to limit the extent of
back-exchange typically translates to very short (and,
therefore, crowded) LC runs, while utilization of more
efficient chromatographic schemes (such as UPLC) may
improve the separation, but results in more extensive
back exchange [81]. While MS detection itself (and
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detection of multiple co-eluting peaks, signal suppres-
sion is likely to result in loss of some of the peptides,
thereby leaving gaps in sequence coverage. Despite
these potential difficulties, significant progress was
made recently in this field, as demonstrated by success-
ful use of HDX MS to probe conformational properties
of larger protein therapeutics, such as 63 kDa -gluco-
cerebrosidase [41], 73 kDa (non-redundant mass) IgG
[43], as well as our own recent work with transferrin
[38, 82], an 80 kDa component of several therapies that
are currently in preclinical evaluation.
Another serious challenge to the characterization of
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biopharmaceuticals often employs “designer” PTMs to
enhance their therapeutic properties. This can be
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[84]. Although mass spectrometry certainly helps to
appreciate the extent of heterogeneity of such engi-
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deed, while ESI MS allows a distinction to be made
among modestly sized protein molecules conjugated to
relatively short PEG chains of varying lengths (e.g., an
8 kDa ubiquitin conjugated to 5 kDa PEG, Figure 11,
top), individual species of larger proteins conjugated to
longer PEG chains cannot be resolved. This is exempli-
fied in Figure 11, bottom, which shows a mass spectrum
of IFN conjugated to 20 kDa PEG. Nevertheless, some
preliminary work carried out in our laboratories indi-
cates that HDX MS can be successfully applied to probe
conformational stability of these systems, and even ionic
charge state distribution analysis may be possible follow-
ing some modifications of the standard routine [49] to
adapt it to continuous, rather than discrete, m/z distribu-
tions. Combination of ion chemistry (in the form of charge
reduction) and separation (ion mobility) in the gas phase
are also currently evaluated as a means to improve the
analysis of these heterogeneous targets [85].
Perhaps the ultimate success of mass spectrometry as
Figure 11. Heterogeneity of protein-polymer conjugates exem-
plified by ESI MS of mono-PEGylated ubiquitin (top) and mono-
PEGylated IFN (bottom). The average molecular weights of the
PEG chains are 5 kDa (ubiquitin) and 20 kDa (IFN). Insets show
mass spectra of unconjugated proteins.a tool to probe conformation of protein drugs and itsacceptance in this capacity will be determined not only
by its ability to deal with very large and highly heter-
ogeneous systems, but by its adaptability to the specific
needs of the biopharmaceutical industry. Several im-
portant questions have to be addressed in order for
mass spectrometry to become an integral part of the
analytical routine in assessing conformation and dy-
namics of biopharmaceutical products. Can it probe
integrity of the higher order structure in a true high-
throughput fashion? Can the entire procedure (from
sample handling to data processing) be automated and
commercialized in a form of an easy-to-use “turn-key”
instrument? What is the reproducibility and robustness
of these measurements if they are carried out in differ-
ent laboratories and/or using different LC-MS plat-
forms? What is the sensitivity of this technique in
detecting small conformational changes and/or alter-
ations of the higher order structure that affect only a
small fraction of the protein molecules? Addressing
these questions will require extensive concerted efforts
of academic and industrial researchers, but the end
result is well worth it. Indeed, adoption of mass spec-
trometry in biopharmaceutical industry in this new role
will not only become a boon to analytical characteriza-
tion, but is also certain to greatly catalyze development
of new and enhance existing potent therapies.
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